Intuitive Surgical Nears Two-Year Low as Investors Ask Whether ISRG Can Rebound Toward $600
Intuitive Surgical Nears Two-Year Low as Investors Ask Whether ISRG Can Rebound Toward $600
Intuitive Surgical, the robotic surgery leader behind the da Vinci surgical system, is back in the spotlight after its stock traded near a two-year low. The sharp pullback has raised a key question for investors: can ISRG recover and move back toward the $600 level?
ISRG Stock Faces Pressure Despite Strong Business Growth
Intuitive Surgical shares recently traded around $433.56, with a market value of about $156 billion. The stock remains far below its 52-week high of about $603.88, showing how much investor sentiment has cooled even though the company continues to report solid operating results.
The weakness appears to be driven less by a collapse in the company’s core business and more by concerns about valuation, future growth expectations, competition, and investor caution toward high-multiple healthcare technology stocks.
Recent Earnings Show the Business Is Still Expanding
In the first quarter of 2026, Intuitive Surgical reported revenue of $2.77 billion, up 23% from the prior year. Instruments and accessories revenue also rose 23% to $1.69 billion, helped by higher da Vinci procedure volume and growth in the Ion platform.
The company placed 431 da Vinci systems in Q1 2026, while da Vinci procedures grew about 16% year over year. These numbers suggest that hospitals and surgeons are still using Intuitive’s robotic systems at a healthy pace.
Why Investors Are Still Nervous
Even with strong sales, investors are watching several risks. First, the stock still trades at a rich valuation, with a price-to-earnings ratio above 52. That means the market expects Intuitive Surgical to keep growing at a strong rate for years. Any sign of slower procedure growth can pressure the share price.
Second, guidance for 2026 procedure growth has been a major focus. Earlier reports noted that the company’s outlook for da Vinci procedure growth was below what some analysts had expected, which helped pressure the stock.
The da Vinci 5 System Remains a Key Growth Driver
The company’s newest robotic platform, da Vinci 5, is central to the long-term bull case. Intuitive Surgical placed 870 da Vinci 5 systems in 2025, compared with 362 in 2024, showing strong adoption of the upgraded system.
If hospitals continue upgrading to da Vinci 5, Intuitive may benefit from system sales, service revenue, and recurring instruments and accessories purchases. This recurring revenue model is one reason many investors still view ISRG as a high-quality healthcare technology company.
Installed Base Gives Intuitive a Strong Moat
At the end of 2025, Intuitive Surgical had about 11,106 da Vinci systems installed worldwide, up 12% from the previous year. Its Ion system installed base also grew to about 995 systems.
This large installed base matters because each system can create repeat revenue through instruments, accessories, and services. In simple terms, Intuitive does not rely only on selling machines. It also benefits every time procedures are performed using its platforms.
Can ISRG Return to $600?
A move back toward $600 is possible, but it would likely require stronger investor confidence. The company may need to show continued procedure growth, steady da Vinci 5 adoption, healthy margins, and limited impact from competition.
From the recent price near $433, a rise to $600 would require a gain of roughly 38%. That is a large move, but not impossible for a company with Intuitive Surgical’s scale, brand strength, and recurring revenue profile.
What Investors Should Watch Next
1. Procedure Growth
Procedure growth is one of the most important indicators for ISRG. More procedures usually mean more demand for instruments and accessories, which are high-value recurring revenue streams.
2. da Vinci 5 Adoption
Investors will want to see whether hospitals keep buying and using da Vinci 5 systems. Strong adoption could support revenue growth and help justify the stock’s premium valuation.
3. Margin Trends
Gross margin and operating margin will remain important. If costs rise faster than revenue, the market may stay cautious.
4. Competition
Large medical device companies are investing in robotic surgery. While Intuitive still has a major lead, growing competition could affect pricing, hospital purchasing decisions, and long-term market share.
Bottom Line
Intuitive Surgical is trading near a two-year low, but the company’s business remains strong. Revenue is growing, procedure volume is rising, and the da Vinci 5 rollout continues to gain traction. However, the stock’s high valuation means investors are demanding clear proof that growth can remain strong.
For ISRG to move back toward $600, the company must keep proving that its robotic surgery ecosystem can expand despite market volatility, competition, and cautious investor sentiment. The stock may not rebound in a straight line, but Intuitive Surgical remains one of the most important companies in the global robotic surgery market.
#IntuitiveSurgical #ISRG #RoboticSurgery #StockMarket #SlimScan #GrowthStocks #CANSLIM